Chemtrail Central
Member's Area
Member List
What's Popular
Who's Linking
Image Database
Search Images
New Images
Link Database
Search Links
New Links
Chemtrail Forum
Active Topics
Who's Online
Flight Explorer
Silver Orbs
News Archive
Top Websites
  Chemtrail Central Forum
  Mycoplasma...the link to many Neurosystemic Diseases

Post New Topic  Post A Reply
profile | register | preferences | faq | search

UBBFriend: Email This Page to Someone! next newest topic | next oldest topic
Topic:   Mycoplasma...the link to many Neurosystemic Diseases

Topic page views:

New Member


posted 03-01-2004 10:31 AM     Click Here to See the Profile for Mech     Edit/Delete Message   Reply w/Quote

Mycoplasma the Linking Pathogen in Neurosystemic Diseases

B y Donald W. Scott, MA, MSc


Pathogenic Mycoplasma
A Common Disease Agent Weaponized
Several strains of mycoplasma have been "engineered" to become more dangerous. They are now being blamed for AIDS, cancer, CFS, MS, CJD and other neurosystemic diseases.

There are 200 species of Mycoplasma. Most are innocuous and do no harm; only four or five are pathogenic. Mycoplasma fermentans (incognitus strain) probably comes from the nucleus of the Brucella bacterium. This disease agent is not a bacterium and not a virus; it is a mutated form of the Brucella bacterium, combined with a visna virus, from which the mycoplasma is extracted.

The pathogenic Mycoplasma used to be very innocuous, but biological warfare research conducted between 1942 and the present time has resulted in the creation of more deadly and infectious forms of Mycoplasma.

Researchers extracted this mycoplasma from the Brucella bacterium and actually reduced the disease to a crystalline form. They "weaponized" it and tested it on an unsuspecting public in North America.

Dr Maurice Hilleman, chief virologist for the pharmaceutical company Merck Sharp & Dohme, stated that this disease agent is now carried by everybody in North America and possibly most people throughout the world.

Despite reporting flaws, there has clearly been an increased incidence of all the neuro/systemic degenerative diseases since World War II and especially since the 1970s with the arrival of previously unheard-of diseases like chronic fatigue syndrome and AIDS.

According to DR Shyh-Ching Lo, senior researcher at The Armed Forces Institute of Pathology and one of America's top mycoplasma researchers, this disease agent causes many illnesses including AIDS, cancer, chronic fatigue syndrome, Crohn's colitis, Type I diabetes, multiple sclerosis, Parkinson's disease, Wegener's disease and collagen-vascular diseases such as rheumatoid arthritis and Alzheimer's.

DR Charles Engel, who is with the US National Institutes of Health, Bethesda, Maryland, stated the following at an NIH meeting on February 7, 2000: "I am now of the view that the probable cause of chronic fatigue syndrome and fibromyalgia is the mycoplasma..."

I have all the official documents to prove that mycoplasma is the disease agent in chronic fatigue syndrome/fibromyalgia as well as in AIDS, multiple sclerosis and many other illnesses.

Of these, 80% are US or Canadian official government documents, and 20% are articles from peer-reviewed journals such as the Journal of the American Medical Association, New England Journal of Medicine and the Canadian Medical Association Journal. The journal articles and government documents complement each other.

How the Mycoplasma Works

The mycoplasma acts by entering into the individual cells of the body, depending upon your genetic predisposition.

You may develop neurological diseases if the pathogen destroys certain cells in your brain, or you may develop Crohn's colitis if the pathogen invades and destroys cells in the lower bowel.

Once the mycoplasma gets into the cell, it can lie there doing nothing sometimes for 10, 20 or 30 years, but if a trauma occurs like an accident or a vaccination that doesn't take, the mycoplasma can become triggered.

Because it is only the DNA particle of the bacterium, it doesn't have any organelles to process its own nutrients, so it grows by uptaking pre-formed sterols from its host cell and it literally kills the cell; the cell ruptures and what is left gets dumped into the bloodstream.

Creation of the Mycoplasma
A Laboratory-Made Disease Agent

Many doctors don't know about this mycoplasma disease agent because it was developed by the US military in biological warfare experimentation and it was not made public. This pathogen was patented by the United States military and DR Shyh-Ching Lo. I have a copy of the documented patent from the US Patent Office.1

All the countries at war were experimenting with biological weapons. In 1942, the governments of the United States, Canada and Britain entered into a secret agreement to create two types of biological weapons (one that would kill, and one that was disabling) for use in the war against Germany and Japan, who were also developing biological weapons.

While they researched a number of disease pathogens, they primarily focused on the Brucella bacterium and began to weaponize it.

From its inception, the biowarfare program was characterized by continuing in-depth review and participation by the most eminent scientists, medical consultants, industrial experts and government officials, and it was classified Top Secret.

The US Public Health Service also closely followed the progress of biological warfare research and development from the very start of the program, and the Centers for Disease Control (CDC) and the National Institutes of Health (NIH) in the United States were working with the military in weaponizing these diseases.

These are diseases that have existed for thousands of years, but they have been weaponized -- which means they've been made more contagious and more effective. And they are spreading.

The Special Virus Cancer Program, created by the CIA and NIH to develop a deadly pathogen for which humanity had no natural immunity (AIDS), was disguised as a war on cancer but was actually part of MKNAOMI.2 Many members of the Senate and House of Representatives do not know what has been going on.

For example, the US Senate Committee on Government Reform had searched the archives in Washington and other places for the document titled "The Special Virus Cancer Program: Progress Report No. 8", and couldn't find it. Somehow they heard I had it, called me and asked me to mail it to them. Imagine: a retired schoolteacher being called by the United States Senate and asked for one of their secret documents!

The US Senate, through the Government Reform Committee, is trying to stop this type of government research.

Crystalline Brucella

The title page of a genuine US Senate Study, declassified on February 24, 1977, shows that George Merck, of the pharmaceutical company, Merck Sharp & Dohme (which now makes cures for diseases that at one time it created), reported in 1946 to the US Secretary of War that his researchers had managed "for the first time" to "isolate the disease agent in crystalline form".3

They had produced a crystalline bacterial toxin extracted from the Brucella bacterium. The bacterial toxin could be removed in crystalline form and stored, transported and deployed without deteriorating. It could be delivered by other vectors such as insects, aerosol or the food chain (in nature it is delivered within the bacterium). But the factor that is working in the Brucella is the mycoplasma.

Brucella is a disease agent that doesn't kill people; it disables them. But, according to DR Donald MacArthur of the Pentagon, appearing before a congressional committee in 1969,4 researchers found that if they had mycoplasma at a certain strength -- actually, 10 to the 10th power (1010) -- it would develop into AIDS, and the person would die from it within a reasonable period of time because it could bypass the natural human defenses.

If the strength was 108, the person would manifest with chronic fatigue syndrome or fibromyalgia. If it was 107, they would present as wasting; they wouldn't die and they wouldn't be disabled, but they would not be very interested in life; they would waste away.

Most of us have never heard of the disease brucellosis because it largely disappeared when they began pasteurizing milk, which was the carrier. One salt shaker of the pure disease agent in a crystalline form could sicken the entire population of Canada. It is absolutely deadly, not so much in terms of killing the body but disabling it.

Because the crystalline disease agent goes into solution in the blood, ordinary blood and tissue tests will not reveal its presence. The mycoplasma will only crystallize at 8.1 pH, and the blood has a pH of 7.4 pH. So the doctor thinks your complaint is "all in your head".

Crystalline Brucella and Multiple Sclerosis

In 1998 in Rochester, New York, I met a former military man, PFC Donald Bentley, who gave me a document and told me: "I was in the US Army, and I was trained in bacteriological warfare. We were handling a bomb filled with brucellosis, only it wasn't brucellosis; it was a Brucella toxin in crystalline form. We were spraying it on the Chinese and North Koreans."

He showed me his certificate listing his training in chemical, biological and radiological warfare. Then he showed me 16 pages of documents given to him by the US military when he was discharged from the service.

They linked brucellosis with multiple sclerosis, and stated in one section: "Veterans with multiple sclerosis, a kind of creeping paralysis developing to a degree of 10% or more disability within two years after separation from active service, may be presumed to be service-connected for disability compensation. Compensation is payable to eligible veterans whose disabilities are due to service."

In other words: "If you become ill with multiple sclerosis, it is because you were handling this Brucella, we will give you a pension. Don't go raising any fuss about it." In these documents, the government of the United States revealed evidence of the cause of multiple sclerosis, but they didn't make it known to the public -- or to your doctor.

In a 1949 report, Drs Kyger and Haden suggested "the possibility that multiple sclerosis might be a central nervous system manifestation of chronic brucellosis". Testing approximately 113 MS patients, they found that almost 95% also tested positive for Brucella.5

We have a document from a medical journal, which concludes that one out of 500 people who had brucellosis would develop what they call neurobrucellosis; in other words, brucellosis in the brain, where the Brucella settles in the lateral ventricles -- where the disease multiple sclerosis is basically located.6

Contamination of Camp Detrick Lab Workers

A 1948 New England Journal of Medicine report titled "Acute Brucellosis Among Laboratory Workers" shows us how actively dangerous this agent is.7 The laboratory workers were from Camp Detrick, Frederick, Maryland, where they were developing biological weapons.

Even though these workers had been vaccinated, wore rubberized suits and masks and worked through holes in the compartment, many of them came down with this awful disease because it is so absolutely and terrifyingly infectious.

The article was written by Lt Calderone Howell, Marine Corps, Captain Edward Miller, Marine Corps, Lt Emily Kelly, United States Naval Reserve, and Captain Henry Bookman. They were all military personnel engaged in making the disease agent Brucella into a more effective biological weapon.

Covert Testing of Mycoplasma
Testing the Dispersal Methods

Documented evidence proves that the biological weapons they were developing were tested on the public in various communities without their knowledge or consent.

The government knew that crystalline Brucella would cause disease in humans. Now they needed to determine how it would spread and the best way to disperse it. They tested dispersal methods for Brucella suis and Brucella melitensis at Dugway Proving Ground, Utah, in June and September 1952.

Probably, 100% of us now are infected with Brucella suis and Brucella melitensis.8

Another government document recommended the genesis of open-air vulnerability tests and covert research and development programs to be conducted by the Army and supported by the Central Intelligence Agency.

At that time, the Government of Canada was asked by the US Government to cooperate in testing weaponized Brucella, and Canada cooperated fully with the United States. The US Government wanted to determine whether mosquitoes would carry the disease and also if the air would carry it.

A government report stated that "open-air testing of infectious biological agents is considered essential to an ultimate understanding of biological warfare potentialities because of the many unknown factors affecting the degradation of micro-organisms in the atmosphere".9

Testing via Mosquito Vector in Punta Gorda, Florida

A report from The New England Journal of Medicine reveals that one of the first outbreaks of chronic fatigue syndrome was in Punta Gorda, Florida, back in 1957.10 It was a strange coincidence that a week before these people came down with chronic fatigue syndrome, there was a huge influx of mosquitoes.

The National Institutes of Health claimed that the mosquitoes came from a forest fire 30 miles away. The truth is that those mosquitoes were infected in Canada by DR Guilford B. Reed at Queen's University. They were bred in Belleville, Ontario, and taken down to Punta Gorda and released there.

Within a week, the first five cases ever of chronic fatigue syndrome were reported to the local clinic in Punta Gorda. The cases kept coming until finally 450 people were ill with the disease.

Testing via Mosquito Vector in Ontario

The Government of Canada had established the Dominion Parasite Laboratory in Belleville, Ontario, where it raised 100 million mosquitoes a month. These were shipped to Queen's University and certain other facilities to be infected with this crystalline disease agent.

The mosquitoes were then let loose in certain communities in the middle of the night, so that the researchers could determine how many people would become ill with chronic fatigue syndrome or fibromyalgia, which was the first disease to show.

One of the communities they tested it on was the St Lawrence Seaway valley, all the way from Kingston to Cornwall, in 1984. They let out hundreds of millions of infected mosquitoes. Over 700 people in the next four or five weeks developed myalgic encephalomyelitis, or chronic fatigue syndrome.

Covert Testing of Other Disease Agents Mad Cow Disease/Kuru/CJD in the Fore Tribe

Before and during World War II, at the infamous Camp 731 in Manchuria, the Japanese military contaminated prisoners of war with certain disease agents.

They also established a research camp in New Guinea in 1942. There they experimented upon the Fore Indian tribe and inoculated them with a minced-up version of the brains of diseased sheep containing the visna virus which causes "mad cow disease" or Creutzfeldt Jakob disease.

About five or six years later, after the Japanese had been driven out, the poor people of the Fore tribe developed what they called kuru, which was their word for "wasting", and they began to shake, lose their appetites and die. The autopsies revealed that their brains had literally turned to mush. They had contracted "mad cow disease" from the Japanese experiments.

When World War II ended, DR Ishii Shiro -- the medical doctor who was commissioned as a General in the Japanese Army so he could take command of Japan's biological warfare development, testing and deployment -- was captured. He was given the choice of a job with the United States Army or execution as a war criminal. Not surprisingly, DR Ishii Shiro chose to work with the US military to demonstrate how the Japanese had created mad cow disease in the Fore Indian tribe.

In 1957, when the disease was beginning to blossom in full among the Fore people, DR Carleton Gajdusek of the US National Institutes of Health headed to New Guinea to determine how the minced-up brains of the visna-infected sheep affected them. He spent a couple of years there, studying the Fore people, and wrote an extensive report. He won the Nobel Prize for "discovering" kuru disease in the Fore tribe.

Testing Carcinogens over Winnipeg, Manitoba

In 1953, the US Government asked the Canadian Government if it could test a chemical over the city of Winnipeg. It was a big city with 500,000 people, miles from anywhere.

The American military sprayed this carcinogenic chemical in a 1,000%-attenuated form, which they said would be so watered down that nobody would get very sick; however, if people came to clinics with a sniffle, a sore throat or ringing in their ears, the researchers would be able to determine what percentage would have developed cancer if the chemical had been used at full strength.

We located evidence that the Americans had indeed tested this carcinogenic chemical -- zinc cadmium sulphide -- over Winnipeg in 1953. We wrote to the Government of Canada, explaining that we had solid evidence of the spraying and asking that we be informed as to how high up in the government the request for permission to spray had gone. We did not receive a reply.

Shortly after, the Pentagon held a press conference on May 14, 1997, where they admitted what they had done. Robert Russo, writing for the Toronto Star11 from Washington, DC, reported the Pentagon's admission that in 1953 it had obtained permission from the Canadian Government to fly over the city of Winnipeg and spray out this chemical -- which sifted down on kids going to school, housewives hanging out their laundry and people going to work.

US Army planes and trucks released the chemical 36 times between July and August 1953. The Pentagon got its statistics, which indicated that if the chemical released had been full strength, approximately a third of the population of Winnipeg would have developed cancers over the next five years.

One professor, DR Hugh Fudenberg, MD, twice nominated for the Nobel Prize, wrote a magazine article stating that the Pentagon came clean on this because two researchers in Sudbury, Ontario -- Don Scott and his son, Bill Scott -- had been revealing this to the public. However, the legwork was done by other researchers!

The US Army actually conducted a series of simulated germ warfare tests over Winnipeg. The Pentagon lied about the tests to the mayor, saying that they were testing a chemical fog over the city, which would protect Winnipeg in the event of a nuclear attack.

A report commissioned by US Congress, chaired by DR Rogene Henderson, lists 32 American towns and cities used as test sites as well.

Brucella Mycoplasma and AIDS

The AIDS pathogen was created out of a Brucella bacterium mutated with a visna virus; then the toxin was removed as a DNA particle called a mycoplasma. They used the same mycoplasma to develop disabling diseases like MS, Crohn's colitis, Lyme disease, etc.

In the previously mentioned US congressional document of a meeting held on June 9, 1969,12 the Pentagon delivered a report to Congress about biological weapons. The Pentagon stated:

"We are continuing to develop disabling weapons."

Dr MacArthur, who was in charge of the research, said:

"We are developing a new lethal weapon, a synthetic biological agent that does not naturally exist, and for which no natural immunity could have been acquired."

Think about it. If you have a deficiency of acquired immunity, you have an acquired immunity deficiency. Plain as that. AIDS.

In laboratories throughout the United States and in a certain number in Canada including at the University of Alberta, the US Government provided the leadership for the development of AIDS for the purpose of population control.

After the scientists had perfected it, the government sent medical teams from the Centers for Disease Control -- under the direction of DR Donald A. Henderson, their investigator into the 1957 chronic fatigue epidemic in Punta Gorda -- during 1969 to 1971 to Africa and some countries such as India, Nepal and Pakistan where they thought the population was becoming too large.13

They gave them all a free vaccination against smallpox; but five years after receiving this vaccination, 60% of those inoculated were suffering from AIDS. They tried to blame it on a monkey, which is nonsense.

A professor at the University of Arkansas made the claim that while studying the tissues of a dead chimpanzee she found traces of HIV. The chimpanzee that she had tested was born in the United States 23 years earlier. It had lived its entire life in a US military laboratory where it was used as an experimental animal in the development of these diseases.

When it died, its body was shipped to a storage place where it was deep-frozen and stored in case they wanted to analyze it later.

Then they decided that they didn't have enough space for it, so they said, "Anybody want this dead chimpanzee?" and this researcher from Arkansas said: "Yes. Send it down to the University of Arkansas. We are happy to get anything that we can get." They shipped it down and she found HIV in it. That virus was acquired by that chimpanzee in the laboratories where it was tested.14

Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis

Chronic fatigue syndrome is more accurately called myalgic encephalomyelitis. The chronic fatigue syndrome nomenclature was given by the US National Institutes of Health because it wanted to downgrade and belittle the disease.

An MRI scan of the brain of a teenage girl with chronic fatigue syndrome displayed a great many scars or punctate lesions in the left frontal lobe area where portions of the brain had literally dissolved and been replaced by scar tissue. This caused cognitive impairment, memory impairment, etc. And what was the cause of the scarring? The mycoplasma.

So there is very concrete physical evidence of these tragic diseases, even though doctors continue to say they don't know where it comes from or what they can do about it.

Many people with chronic fatigue syndrome, myalgic encephalomyelitis and fibromyalgia who apply to the Canada Pensions Plan Review Tribunal will be turned down because they cannot prove that they are ill.

During 1999 I conducted several appeals to Canada Pensions and the Workers Compensation Board (WCB, now the Workplace Safety and Insurance Board) on behalf of people who have been turned down. I provided documented evidence of these illnesses, and these people were all granted their pensions on the basis of the evidence that I provided.

In March 1999, for example, I appealed to the WCB on behalf of a lady with fibromyalgia who had been denied her pension back in 1993. The vice-chairman of the board came to Sudbury to hear the appeal, and I showed him a number of documents which proved that this lady was physically ill with fibromyalgia. It was a disease that caused physical damage, and the disease agent was a mycoplasma.

The guy listened for three hours, and then he said to me: "Mr Scott, how is it I have never heard of any of this before? I said: "We brought a top authority in this area into Sudbury to speak on this subject and not a single solitary doctor came to that presentation."

Testing For Mycoplasma In Your Body Polymerase Chain Reaction Test

Information is not generally available about this agent because, first of all, the mycoplasma is such a minutely small disease agent. A hundred years ago, certain medical theoreticians conceived that there must be a form of disease agent smaller than bacteria and viruses.

This pathogenic organism, the mycoplasma, is so minute that normal blood and tissue tests will not reveal its presence as the source of the disease.

Your doctor may diagnose you with Alzheimer's disease, and he will say: "Golly, we don't know where Alzheimer's comes from. All we know is that your brain begins to deteriorate, cells rupture, the myelin sheath around the nerves dissolves, and so on." Or if you have chronic fatigue syndrome, the doctor will not be able to find any cause for your illness with ordinary blood and tissue tests.

This mycoplasma couldn't be detected until about 30 years ago when the polymerase chain reaction (PCR) test was developed, in which a sample of your blood is examined and damaged particles are removed and subjected to a polymerase chain reaction. This causes the DNA in the particles to break down.

The particles are then placed in a nutrient, which causes the DNA to grow back into its original form. If enough of the substance is produced, the form can be recognized, so it can be determined whether Brucella or another kind of agent is behind that particular mycoplasma.

Blood Test

If you or anybody in your family has myalgic encephalomyelitis, fibromyalgia, multiple sclerosis or Alzheimer's, you can send a blood sample to Dr Les Simpson in New Zealand for testing.

If you are ill with these diseases, your red blood cells will not be normal doughnut-shaped blood cells capable of being compressed and squeezed through the capillaries, but will swell up like cherry-filled doughnuts which cannot be compressed.

The blood cells become enlarged and distended because the only way the mycoplasma can exist is by uptaking pre-formed sterols from the host cell. One of the best sources of pre-formed sterols is cholesterol, and cholesterol is what gives your blood cells flexibility.

If the cholesterol is taken out by the mycoplasma, the red blood cell swells up and doesn't go through, and the person begins to feel all the aches and pains and all the damage it causes to the brain, the heart, the stomach, the feet and the whole body because blood and oxygen are cut off.

And that is why people with fibromyalgia and chronic fatigue syndrome have such a terrible time. When the blood is cut off from the brain, punctate lesions appear because those parts of the brain die. The mycoplasma will get into portions of the heart muscle, especially the left ventricle, and those cells will die.

Certain people have cells in the lateral ventricles of the brain that have a genetic predisposition to admit the mycoplasma, and this causes the lateral ventricles to deteriorate and die.

This leads to multiple sclerosis, which will progress until these people are totally disabled; frequently, they die prematurely. The mycoplasma will get into the lower bowel, parts of which will die, thus causing colitis. All of these diseases are caused by the degenerating properties of the mycoplasma.

In early 2000, a gentleman in Sudbury phoned me and told me he had fibromyalgia. He applied for a pension and was turned down because his doctor said it was all in his head and there was no external evidence. I gave him the proper form and a vial, and he sent his blood to DR Simpson to be tested.

He did this with his family doctor's approval, and the results from DR Simpson showed that only 4% of his red blood cells were functioning normally and carrying the appropriate amount of oxygen to his poor body, whereas 83% were distended, enlarged and hardened, and wouldn't go through the capillaries without an awful lot of pressure and trouble. This is the physical evidence of the damage that is done.

ECG Test

You can also ask your doctor to give you a 24-hour Holter ECG. You know, of course, that an electrocardiogram is a measure of your heartbeat and shows what is going on in the right ventricle, the left ventricle and so on. Tests show that 100% of patients with chronic fatigue syndrome and fibromyalgia have an irregular heartbeat.

At various periods during the 24 hours, the heart, instead of working happily away going "bump-BUMP, bump-BUMP", every now and again goes "buhbuhbuhbuhbuhbuhbuhbuhbuh". The T-wave (the waves are called P, Q, R, S and T) is normally a peak, and then the wave levels off and starts with the P-wave again. In chronic fatigue and fibromyalgia patients, the T-wave flattens off, or actually inverts.

That means the blood in the left ventricle is not being squeezed up through the aorta and around through the body.

My client from Sudbury had this test done and, lo and behold, the results stated: "The shape of T and S-T suggests left ventricle strain pattern, although voltage and so on is normal." The doctor had no clue as to why the T-wave was not working properly.

I analyzed the report of this patient who had been turned down by Canada Pensions and sent it back to them. They wrote back, saying: "It looks like we may have made a mistake. We are going to give you a hearing and you can explain this to us in more detail."

So it is not all in your imagination.

There is actual physical damage to the heart. The left ventricle muscles do show scarring. That is why many people are diagnosed with a heart condition when they first develop fibromyalgia, but it's only one of several problems because the mycoplasma can do all kinds of damage.

Blood Volume Test

You can also ask your doctor for a blood volume test. Every human being requires a certain amount of blood per pound of body weight, and it has been observed that people with fibromyalgia, chronic fatigue syndrome, multiple sclerosis and other illnesses do not have the normal blood volume their body needs to function properly. Doctors aren't normally aware of this.

This test measures the amount of blood in the human body by taking out 5 cc, putting a tracer in it and then putting it back into the body. One hour later, take out 5 cc again and look for the tracer. The thicker the blood and the lower the blood volume, the more tracer you will find.

The analysis of one of my clients stated: "This patient was referred for red cell mass study. The red cell volume is 16.9 ml per kg of body weight. The normal range is 25 to 35 ml per kg. This guy has 36% less blood in his body than the body needs to function." And the doctor hadn't even known the test existed.

If you lost 36% of your blood in an accident, do you think your doctor would tell you that you are alright and should just take up line dancing and get over it? They would rush you to the nearest hospital and start transfusing you with blood. These tragic people with these awful diseases are functioning with anywhere from 7% to 50% less blood than their body needs to function.

Undoing The Damage

The body undoes the damage itself. The scarring in the brain of people with chronic fatigue and fibromyalgia will be repaired. There is cellular repair going on all the time. But the mycoplasma has moved on to the next cell.

In the early stages of a disease, doxycycline may reverse that disease process. It is one of the tetracycline antibiotics, but it is not bactericidal; it is bacteriostatic -- it stops the growth of the mycoplasma. And if the mycoplasma growth can be stopped for long enough, then the immune system takes over.

Doxycycline treatment is discussed in a paper by mycoplasma expert Professor Garth Nicholson, PhD, of the Institute for Molecular Medicine.15 DR Nicholson is involved in a US$8-million mycoplasma research program funded by the US military and headed by DR Charles Engel of the NIH.

The program is studying Gulf War veterans, 450 of them, because there is evidence to suggest that Gulf War syndrome is another illness (or set of illnesses) caused by mycoplasma.


Nexus Magazine Volume 8, Number 5 September/October 2001


Donald W. Scott, MA, MSc
President The Common Cause
Medical Research Foundation
190 Mountain Street, Suite 405
Sudbury, Ontario, Canada P3B 4G2
Tel/fax: +1 (705) 670 0180



This is an excellent review of mycoplasmas. My main experience with them is in their association with rheumatoid arthritis. I have successfully treated well over 2,000 patients with RA with a combination of my eating plan, NST and the low dosed pulse antibiotic program (see below).

Since I have incorporated NST into the program it seems the need for the antibiotics to resolve the infection has decreased quite dramatically and I only need to use the antibiotics for those with advanced disease.


Recommended Reading:

¥ Horowitz, Leonard, Emerging Viruses: Aids and Ebola, Tetrahedron Publishing, USA, 1996.

¥ Johnson, Hillary, Osler's Web, Crown Publishers, New York, 1996.

¥ Scott, Donald W. and William L. C. Scott, The Brucellosis Triangle, The Chelmsford Publishers (Box 133, Stat. B., Sudbury, Ontario P3E 4N5), Canada, 1998 (US$21.95 + $3 s&h in US).

¥ Scott, Donald W. and William L. C. Scott, The Extremely Unfortunate Skull Valley Incident, The Chelmsford Publishers, Canada, 1996 (revised, extended edition available from mid-September 2001; US$16.00 pre-pub. price + US$3 s&h in US).

¥ The Journal of Degenerative Diseases (Donald W. Scott, Editor), The Common Cause Medical Research Foundation (Box 133, Stat B., Sudbury, Ontario, P3E 4N5), Canada (quarterly journal; annual subscription: US$25.00 in USA, $30 foreign).

Additional Contacts:

¥ Ms Jennie Burke, Australian Biologics, Level 6, 383 Pitt Street, Sydney NSW 2000, Australia tel +61 (0)2 9283 0807, fax +61 (0)2 9283 0910. Australian Biologics does tests for mycoplasma.

¥ Consumer Health Organization of Canada, 1220 Sheppard Avenue East #412, Toronto, Ontario, Canada M2K 2S5, Tel +1 (416) 490 0986, website

¥ Professor Garth Nicholson, PhD, Institute for Molecular Medicine, 15162 Triton Lane, Huntington Beach, CA, 92649-1401, USA, Tel +1 (714) 903 2900.

¥ DR Les Simpson, Red Blood Cell Research Ltd, 31 Bath Street, Dunedin, 9001, New Zealand, Tel +64 (0)3 471 8540, email (Note: DR Simpson directs his study to red cell shape analysis, not the mycoplasma hypothesis.)


Related Articles:

Physicians' Protocol For Using Antibiotics in Rheumatic Disease

Mycoplasma Bacteria Tied To Chronic Illness

Identification of Mycoplasma in Synovial Fluid of Arthritis Patients


1. "Pathogenic Mycoplasma", US Patent No. 5,242,820, issued September 7, 1993. Dr Lo is listed as the "Inventor" and the American Registry of Pathology, Washington, DC, is listed as the "Assignee".

2. "Special Virus Cancer Program: Progress Report No. 8", prepared by the National Cancer Institute, Viral Oncology, Etiology Area, July 1971, submitted to NIH Annual Report in May 1971 and updated July 1971.

3. US Senate, Ninety-fifth Congress, Hearings before the Subcommittee on Health and Scientific Research of the Committee on Human Resources, Biological Testing Involving Human Subjects by the Department of Defense, 1977; released as US Army Activities in the US Biological Warfare Programs, Volumes One and Two, 24 February 1977.

4. Dr Donald MacArthur, Pentagon, Department of Defense Appropriations for 1970, Hearings before Subcommittee of the Committee on Appropriations, House of Representatives, Ninety-First Congress, First Session, Monday June 9, 1969, pp 105&endash;144, esp. pp. 114, 129.

5. Kyger, E. R. and Russell L. Haden, "Brucellosis and Multiple Sclerosis", The American Journal of Medical Sciences 1949:689-693.

6. Colmonero et al., "Complications Associated with Brucella melitensis Infection: A Study of 530 Cases", Medicine 1996;75(4).

7. Howell, Miller, Kelly and Bookman, "Acute Brucellosis Among Laboratory Workers", New England Journal of Medicine 1948;236:741.

8. "Special Virus Cancer Program: Progress Report No. 8", ibid., table 4, p. 135.

9. US Senate, Hearings before the Subcommittee on Health and Scientific Research of the Committee on Human Resources, March 8 and May 23, 1977, ibid.

10. New England Journal of Medicine, August 22, 1957, p. 362.

11. Toronto Star, May 15, 1997.

12. Dr Donald MacArthur, Pentagon, Department of Defense Appropriations for 1970, Hearings, Monday June 9, 1969, ibid., p. 129.

13. Henderson, Donald A., "Smallpox: Epitaph for a Killer", National Geographic, December 1978, p. 804.

14. Blum, Deborah, The Monkey Wars, Oxford University Press, New York, 1994.

15. Nicholson, G. L., "Doxycycline treatment and Desert Storm", JAMA 1995;273:618-619.

IP Logged

New Member

Knoxville Tennessee
6 posts, Apr 2004

posted 04-03-2004 05:47 PM     Click Here to See the Profile for piratenews   Visit piratenews's Homepage!   Edit/Delete Message   Reply w/Quote

A Weapon to Fight the AIDS War

by Boyd Graves

Recently I had an opportunity of a lifetime where I went to San Diego, California in search of an AIDS (mycoplasma) cure.

On November 19, 2001, I received a 20 minute injection of TETRASIL (Ag4O4). Within 90 seconds most of the chronic pain I had disappeared!

We are going to follow my T-cell count and viral load for the next six months. Even if the pain returns, it has been a WONDERFUL feeling to be pain-free.

The one-time injection of TETRASIL may not be a complete "miracle cure", however, for those of us who have not experienced relief from mycoplasma infections, it is a God-send.

If you are interested in learning more about this wonderful treatment (patented in the U.S. in 1997), get in touch with me. I can be reached at 216-721-3865.

Take control of your life and health. Ask questions, research and take action. We have within our reach, the ability to help ourselves. It is your turn.

If you have not already done so, download the govt FLOW CHART at my web archives: and sign our petition for government review and investigation of the U.S. Special Virus program and Flow Chart. TETRASIL does appear to give mycoplasmas a 'bad hair day', and that is truly a good thing.

Please share this email widely. We CAN make a difference!


Boyd E. Graves, J.D., Activist & New Author
"STATE ORIGIN: The Evidence of the Laboratory Birth of AIDS".
E- Book Download at

For more information call me at 216-721-3865
or 1-800-257-9387, email me
or write to:

Dr. Boyd E. Graves
c/o Zygote Media
PO Box 332
Abilene, KS 67410-0332

Thank you.

Tetrasilver Tetroxide

[Patented cure for AIDS/HIV/mycoplasma, Gulf War mycoplasma, Cancer, Infectious Alcoholism and damn near everything else]



Marantech Holding was organized in April 1999 as a Delaware limited liability company (LLC). Headquarters are in Providence, Rhode Island, USA, with additional research based in Israel.

Marantech's founder and inventor, Dr. Marvin S. Antelman, is a physical chemist known internationally for his scientific discoveries and many highly successful commercial applications (e.g., Thin Layer Chromatography used worldwide by scientists; Micro battery technology used to power credit cards and other applications; A method to eliminate deep sea corrosion of zirconium in nuclear submarine reactors).

Marantech was formed to research, develop and commercialize a unique category of inorganic compounds. All are multivalent metallic oxides that function as electron-firing molecular-scale nano devices. This class, characterized by Dr. Antelman and subsequently named ELECTRON-JUMPING COMPOUNDS® (EJC®) has broad and significant potential applications in medical, industrial and consumer markets.

A seasoned management team and distinguished consulting, medical, and scientific advisory groups are guiding the company through its current stage.


Electron-Jumping Compounds® (EJCs) represent a class of multivalent metallic oxides that function as electron-firing molecular-scale nano devices.

To date the company has identified eight EJCs and fully patented their potential market applications. Each EJC is based on a different metallic oxide, including silver, iron, manganese, cobalt, praseodymium, terbium, copper and bismuth.

EJCs have a natural attraction to specific biochemical functional groups of the elements sulfur, nitrogen and phosphorous, one of which is expressed by certain proteins on the membrane surface of cancer cells and all rapidly proliferating pathogens (bacteria, fungi, viruses, and protozoa).

Upon contact, a multi-stage chemical reaction is triggered:

* Covalent bonding with the target
* Release of electrical energy (nano-electrocution) through a reduction/oxidation process
* Release of highly active singlet oxygen.

This action effectively ensures the target's death. No other drug or anti-microbial functions in this way. The unique method of action of the Company's compounds has the potential to establish a new class of medicine.

Below is a graphic illustration of EJC's proposed mechanism of action between TST and HIV. A similar mechanism of action is associated with the company's seven other EJCs. Depending on the target pathogen, the attracting biochemical functional group may either be sulfur, nitrogen or phosphorus.

Most importantly, in medical applications, normal tissues appear to be unaffected when Marantech's EJCs are applied in low, pharmaceutically effective concentrations. Additionally, what is most interesting is that because of the compound's ability to deliver an electrical shock, pathogens may be unable to develop resistance or mutation strategies. This could have profound implications for the world's health and safety and answer one of the leading problems facing today's pharmaceutical and biotech industry.

Status of Testing and Next Steps

Some of the leading contract research organizations (CROs) in the world have conducted laboratory analysis of Marantech's EJCs, including the company's most thoroughly tested EJC, Tetrasilver Tetroxide (TST™). Each CRO has provided independent assessment of its potential.

Results of in-vitro tests showed that a very wide spectrum of gram-negative and gram-positive bacteria were destroyed, including some of the leading antibiotic-resistant bacteria, viruses, protozoa and fungi in low concentrations. The independent analysis also indicated TST's ability to destroy cancer cells and inhibit their reproduction. Toxicity analysis and early-stage clinical studies have also been performed.

Several patents and patents pending protect the EJC intellectual property.


Aidance Pharmaceutical (a division of Marantech) was formed in 2002 to continue core research and fully develop the Company's compounds for systemic infectious diseases and cancer therapeutics (skin and systemic).

Infectious Diseases

Status: In independent testing, HIV, the virus that causes AIDS (Acquired Immune Deficiency Syndrome) was destroyed (98.4%) in-vitro with concentrations as low as 20 parts-per-million. Toxicity analysis in-vitro and in mice showed that the company's Tetrasilver Tetroxide (TST) does not produce toxic side effects and that healthy tissues are not effected. Because of documented non-toxicity, a limited number of terminally ill AIDS patients suffering from Wasting Syndrome, Candidiasis and P. Carinii Pneumonia have been treated in clinics outside the US. Thirty days after treatment, clinics reported an increase in patient body weight, white blood cells and other key markers.

Because TST is a broad-spectrum anti-pathogen, when administered to AIDS patients it apparently destroys many of the opportunistic infectious diseases that usually accompany HIV/AIDS.

Laboratory and clinical analysis has also documented the ability of TST to destroy the Herpes Simplex virus (HSV-1 and HSV-2) in concentrations below 96 PPM. Limited human clinical studies have produced encouraging results.

The Company expects to continue testing TST against HIV and related opportunistic infections as funding allows.

Several patents and patents pending protect the intellectual property within the areas of infectious disease.

Potential: Infectious diseases have been on the increase worldwide and show no signs of abatement. Antibiotics have no affect on viruses, and bacteria are able to mutate so effectively that antibiotics have diminishing ability to inhibit bacterial growth. In developed countries, as many as 60% of hospital-acquired infections are caused by drug-resistant microbes. Over half of all hospitalized patients are treated with antibiotics. Antibiotics represent a significant portion of overall healthcare costs, accounting for between 20% and 50% of total hospital drug expenditures. TST may offer an alternative to antibiotics.

More people have died from HIV/AIDS over the last twenty years than from any other disease in human history. IMUSIL® (TST formulated for intravenous use) may offer an alternative to other anti-HIV drugs (which are highly susceptible to HIV mutation, can cause severe side effects in patients, require daily dosages, and are very costly). Currently, over 40 million people worldwide suffer from this pandemic, mostly outside the US. Estimates show that a global campaign against the epidemic needs $7-10 billion annually for an effective response in low- and middle-income countries.

Because IMUSIL operates on an entirely different principle from other drugs (including antibiotics and antiretroviral drugs), the Company's compounds may offer an important alternative in the global fight against infectious diseases.

Next: Outside the US, two (2) clinical trials will be conducted in the coming months using IMUSIL against HIV/AIDS. Based on further documentation of IMUSIL's efficacy, the Company hopes to receive approval from Ministries of Health in selected countries outside the US for IMUSIL treatment.

Next steps for infectious diseases also include ongoing pre-clinical and clinical research, regulatory new drug application, expanding the medical advisory and management group, and exploring potential strategic alliances.

For additional information, please contact us.

Cancer Therapeutics

Status: A leading independent laboratory tested the effect of TST in-vitro on cultures of a variety of cancer cell lines, including human breast, colon, kidney, leukemia, liver, lung, lymphoma, melanoma, pancreas, prostate and stomach. Results from multiple testing revealed the low-concentration ability of TST to destroy these cancer cells upon contact.

Additional independent testing with TST also documented the compound's ability to inhibit the production of cervical and mammary cancer cells. Subsequent testing has confirmed TST's ability to covalently bind with cancer protein and destroy cancer cells. Marantech also contracted for an independent dermatological clinical analysis, including topical treatment of various skin and mucosal tumors with TETRASIL® (the company's topical formulation). Promising preliminary results, verified by biopsy, were reported, including apparent elimination of cancerous cells in many patients with malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Karposi's sarcoma, early stage cases of Paget's disease (nipple carcinoma), and cervical cancer. Results were encouraging and no adverse side effects were observed.

Several patents and patents pending protect the intellectual property within the areas of cancer therapeutics.

Potential: Scientists predict that by the year 2020 there will be 15 million new cases of cancer worldwide each year, and 10 million deaths. Cancer costs Americans alone more than an estimated $107 billion annually. TST systemic and topical therapeutic products may offer a significant alternative to existing cancer therapies.

Next: The Company is exploring strategic alliances and licensing agreements for funding and development of the company's EJC technology for cancer therapeutics.


Aidance Skincare & Topical Solutions (a division of Marantech) is focused on fully developing the Company's EJC technology for the treatment of non-cancerous skin conditions and diseases, including commercializing the division's topical ointment (Tetrasil®).

Status: Independent laboratory and clinical studies commissioned by Marantech indicate that topically applied TETRASIL ointment may lead to improvements in a range of infection-related skin conditions (bacterial, viral, fungal), including cold sores, genital herpes, conjunctivitis, chickenpox, shingles, diabetic leg and foot ulcers, dermal tuberculosis [mycoplasma] and ringworm. Clinical studies also indicate that TETRASIL ointment may promote healing of skin conditions that are neither cancerous nor infection-related, including atopic dermatitis (eczema), psoriasis, poison ivy, and third-degree burns, apparently by both disinfecting the area and triggering an increase in the production of new, healthy skin tissue.

In multiple tests, TETRASIL has proved to be non-toxic. Limited human use of TETRASIL by over 500 patients with some of the above-named skin conditions has produced impressive results and strong testimonials.

Several patents and patents pending protect the intellectual property topical applications of EJCs.

Potential: Several viral, bacterial, fungal and other skin conditions present vexing challenges for the medical community and patients, and TETRASIL may offer an important and timely solution.

107 million people worldwide suffer from Genital and Oral Herpes. In the last two decades, genital herpes has doubled among white adults in their 20s while increasing fivefold among white teenagers, according to the U.S. Centers for Disease Control and Prevention. Now, about one in five teens and adults (some 45 million Americans) has the disease. A recent study estimates that 49 percent of women aged 15 to 39 will be infected with herpes simplex virus type 2 by 2025 if present trends continue. The associated medical costs would rise to $2.7 billion in 2025, from $1.8 billion in 2000. Initial clinical studies and anecdotal reports indicate that TETRASIL is effective against herpes and may offer a viable alternative to current medications.

The wound care market is a $10 billion worldwide industry. In the US alone, this market was estimated to be about $3.7 billion in the year 2000, with a compounded annual growth rate of about 3%. Market data for 2001 indicate that with an estimated 6.6 million patients nationally having pressure ulcers, an estimated $5 billion is spent annually for treatment. The two main types of chronic bacterially induced wounds of concern to the Company are diabetic foot ulcers and decubital ulcers (pressure ulcers, bed sores, etc.). This is a larger market than burns or traumatic and surgically induced wounds combined. In clinical studies and patient testimonials, TETRASIL has shown efficacious results against these types of ulcers.

Next: Clinical studies for TETRASIL will continue in 2003 at selected hospitals inside and outside the US. Current pending studies are focused on pressure ulcers (bedsores) and topical human papilloma virus (HPV) and/or genital warts infection.

Sales of TETRASIL in the US have already commenced. TETRASIL is currently sold without FDA approval as a no-claim product ( Outside the US, the Company has begun shipping TETRASIL in collaboration with key distribution partners. Approval of TETRASIL, either as a cosmetic or pharmaceutical, in selected countries outside is expected to generate modest to significant income within the next few years.

Additional next steps include ongoing laboratory and clinical research, continued commercialization of TETRASIL, FDA new drug application, as well as ongoing application with foreign ministries of health for approval of TETRASIL, and expanding the medical advisory and skincare management group.

Method of curing AIDS with tetrasilver tetroxide molecular crystal devices

United States Patent 5,676,977
Inventors: Antelman; Marvin S. (Rehovot, IL)
Assignee: Antelman Technologies Ltd. (Providence, RI)
October 14, 1997
Filed: May 31, 1996


The diamagnetic semiconducting molecular crystal tetrasilver tetroxide (Ag.sub.4 O.sub.4) is utilized for destroying the AIDS virus, destroying AIDS synergistic pathogens and immunity suppressing moieties (ISM) in humans. A single intravenous injection of the devices is all that is required for efficacy at levels of about 40 PPM of human blood. The device molecular crystal contains two mono and two trivalent silver ions capable of "firing" electrons capable of electrocuting the AIDS virus, pathogens and ISM. When administered into the bloodstream, the device electrons will be triggered by pathogens, a proliferating virus and ISM, and when fired will simultaneously trigger a redox chelation mechanism resulting in divalent silver moieties which chelate and bind active sites of the entities destroying them. The devices are completely non-toxic. However, they put stress on the liver causing hepatomegaly, but there is no loss of liver function.

What is claimed is:

1. A method of treating AIDS-afflicted humans comprising injecting a multitude of tetrasilver tetroxide molecular crystals into the bloodstream of the human subject.
2. A method for increasing white blood cell counts in AIDS-afflicted humans comprising injecting a multitude of tetrasilver tetroxide molecular crystals into the bloodstream of the human subject.
3. Methods of treating AIDS-affilicted humans according to claims 1-2 where the concentration of said molecular crystals is approximately 40 PPM of the total blood weight of the human subject.


The present invention relates to the employment of molecular crystals as anti-AIDS devices, but more particularly to the molecular crystal semiconductor tetrasilver tetroxide Ag.sub.4 O.sub.4 which has two monovalent and two trivalent silver ions per molecule, and which through this structural configuration enables intermolecular electron transfer capable of killing viruses and binding them to the resulting silver entity so that a single intravenous injection will completely obliterate acquired immune deficiency syndrome (AIDS) in humans. Furthermore, said devices are capable of killing pathogens and purging the bloodstream of immune suppressing moieties (ISM) whether or not created by the AIDS virus (HIV); so as to restore the immune system.

The present invention is based on concepts previously elucidated in applicant's U.S. Pat. No. 5,336,499 which discloses the destruction and inhibition of bacteria, algae and the AIDS virus in nutrient life supporting systems by using said silver oxide devices. Example 3 of said patent discloses that 18 PPM of said crystal devices could totally suppress the AIDS virus (page 6, line 5). Subsequent to the filing of the aforementioned patent, further testing revealed complete 100% destruction of the AIDS virus in vitro at 20 PPM, and the fact that said devices were harmless when ingested and inhaled, being non-toxic.

Encouraged by these evaluations and successes, applicant obtained permission to evaluate the crystals in vitro against murine acquired immune deficiency syndrome (MAIDS). Only one facility in the State of Israel is licensed for these evaluations, namely, the Kaplan Hospital in Rehovot, Israel, which is affiliated with the Hebrew University-Hadassah Medical School where said evaluations were done.

The initial evaluations entailed experimenting with various silver moieties cited in applicant's aforementioned patent, concentrations, non-reactive buffers and modes of administration. After about 18 months of judicious efforts and initial failures, success was finally achieved in destroying the MAIDS virus in C57BL mice with a single intravenous injection. The results of this test program comprise Example 5 of U.S. Pat. No. 5,336,499. After success with mice, the inventor was able to test the efficacy of said devices on two select etiological groups of terminal AIDS patients in a clinic in Tegucigalpa, Honduras, Central America.

The AIDS patients comprised the etiological subgroups, Candidiasis and Wasting Syndrome. Current indicator diseases for diagnosing AIDS which have been expanded by the CDC, fall into the following five major categories with the approximate percent distribution among AIDS patients:

1. P. carinii pneumonia 51%
2. Wasting syndrome 19%
3. Candidiasis 13%
4. Kaposi's sarcoma 11%
5. Dementia 6%

This invention concerns itself with the treatment and cure of candidiasis and wasting syndrome AIDS patients with Tetrasil*. These two groups account for approximately one third of AIDS cases.

*Trademark of Holipharm Corporation (of Israel) for Ag.sub.4 O.sub.4

Stedman's Medical Dictionary (Williams & Wilken's 26th Ed., 1995) defines wasting syndrome "as a condition of 10% weight loss in conjunction with diarrhea or fever . . . Associated with AIDS (p. 1744)."


The main object of the invention is to provide for a molecular scale device of a single tetrasilver tetroxide crystalline molecule capable of restoring the immunity of AIDS afflicted humans of the two AIDS etiological subgroups, candidiasis and wasting syndrome.

Another object of the invention is to provide for immunity restoration in said AIDS afflicted humans through a single injection.

Another object of this invention is to destroy ISM in humans manifesting AIDS diseases of said AIDS etiological subgroups irrespective as to whether said ISM was HIV induced, since it is known that humans may manifest AIDS and still be HIV negative, and thus restore the immune system in said humans.

Another object of this invention is to destroy the AIDS virus when present in the systems of said AIDS afflicted humans.


This invention relates to a molecular scale device not only capable of destroying the AIDS virus, but of purging the human bloodstream of pathogens and restoring immunity to AIDS patients of the candidiasis and wasting syndrome categories. Said molecular device consists of a single crystal of tetrasilver tetroxide (Ag.sub.4 O.sub.4). The crystal lattice of this molecule has a unique structure since it is a diamagnetic semiconducting crystal containing two mono and two trivalent silver ions, which in effect are capable of "firing" electrons under certain conditions which will destroy AIDS viruses, other pathogens and immune suppressing moieties (ISM), not only through the electrocution mode, but also by a binding process which occurs simultaneously with electron firing, namely, binding and chelation of divalent silver, i.e., the resulting product of the electron transfer redox that occur when the monovalent silver ions are oxidized and the trivalent ions are reduced in the crystal. The binding/chelation effect occurs at active sites of the AIDS virus, pathogens and ISM. Because of the extremely minute size of a single molecule of this crystal, several million of these devices may be employed in concert to destroy a virus colony to purge a life support system of ISM and pathogens with the consumption of only parts per trillion of the crystal devices. Thus an optimum of 40 PPM of the devices by weight of human blood was found to be sufficient to completely obliterate AIDS. This concentration is slightly over double of the optimum concentration recommended in applicant's aforementioned U.S. patent for the destruction of the human AIDS virus in vitro. Other details concerning the structure of the crystal and its mechanism against pathogens, the AIDS virus and ISM would analogously hold here, and have already been further elucidated in said patent.

$10 DIY Homebrew Colloidal Silver Generator Kit from Radio Shack detailed by Intelligence Report radio host Mark Koernke (and John Stadtmiller), substituted by his wife Nancy Koernke who hosts her own show The Kitchen Militia.

99.9% Silver Rods:


29 January 2004

Below is a copy of a letter recently sent to the President of the Global Health Council. While acknowledging the truth is important, this letter is being made public not in order to blame or to stir citizens to anger. Rather it is intended to help spread knowledge of the cure, tetrasilver tetroxide. Silver and oxygen anyone?

January 25, 2004
Dr. Nils Daulaire
President & CEO
Global Health Council

Re: The U.S. CURE and Origin of AIDS

Dear Dr. Daulaire:

My name is Boyd Ed Graves. I am a nominee for the Jonathan Mann award (2003). Since my HIV diagnosis in 1992, I have worked tirelessly to focus the AIDS debate on its U.S. origin and of late, its CURE patented by the United States in 1997. Twenty-six months ago, I took the one time injection cure for AIDS. My medical records are maintained by the Veteranís Hospital administration in La Jolla, California and Cleveland, Ohio. Last August I was released from HIV/AIDS medical care in La Jolla and two weeks ago, the VA hospital in Cleveland confirmed that my viral load is undetectable.

The AIDS CURE is effective and it will eventually be so very cheap. We recently alerted your web-master to the AIDS CURE and he has asked to be removed from any further emails regarding the CURE.

We find your pronouncement concerning the Presidentís State of the Union address somewhat baffling in light of the desires f your web- master to not receive any further notification regarding the development of the cure, and its eventual implementation. We sincerely believe an immedia te "double blind" study "TETRASIL/IMUSIL", patent #5676977 should begin without further delay.

We implore you to peruse the seven-year old patented cure for AIDS and subsequently provide the leadership this issue so desperately needs.

We have thus far found the planet "empty" of genuine compassion towards the victims of this U.S. weapon of mass destruction. According to the experts, HIV/AIDS is the designer virus of the U.S. Special Virus program (1948 -1978). see:

The program's 1971 "research logic" flowchart is irrefutable proof the development of AIDS was not by accident. see:

We are hopeful we have reached the heart of the AIDS paradigm in our opening letter to you here. We deeply believe the Global Health Council has an added obligation to implement the AIDS cure and review the U.S. Special Virus program.

We have been met with silence and inaction from the U.S press, particularly, the Cleveland Plain Dealer, my hometown newspaper. They simply refuse to print, anything on this issue that has come from the people, even if it can all be verified and corroborated. It is clear that there are U.S. directives in place compelling the media to be abridged, the Congress to remain silent and law enforcement to strong-arm any effort to uncover the truth. It is clear that the development of HIV/AIDS is outlined specifically in a number of U.S. policy decisions. See, inter alia, U.S. Public Law 91-213 (3/16/70) and H.R. 15090, Part VI funding, page 129 (SYNTHETIC BIOLOGICAL AGENT). Additionally, there are fifteen progress reports of the secret, federal virus development program.

By flooding the world with TETRASIL, we can envision a world once again without HIV/AIDS. This cannot be achieved without your direct and steady involvement.

We are hopeful for the people of the planet.

Boyd Ed Graves, J.D.

Director-AIDS Concerns
The Common Cause
Medical Research Foundation
1008 Elbon Rd.
Cleveland Heights, OH44121

Tetrasilver Tetra-oxide

AIDS Forum

Hi Folks! I received Tetrasil by I.V. drip, in a sterile water solution, last week. We were uncertain about the buffer solution, as it had to be nonreactive, and pH 6.5, so opted for (nonsaline) water. The water tested at 6, so that seemed O.K. The drip was set for about 3 hours. The tetrasil went into solution alright, but after it was all done, there was a residue in the bottom of the bag. Hopefully, I got enough of it. The doctor told me that nonsaline water causes red blood cells to burst (easily replaced), and I guess that accounts for the ache in my hand & wrist (a vein in my hand was used) during the drip, and my hand swelled up somewhat afterwards. I probably should have investigated more thoroughly, what the buffer solution should have been. Haste!--I just wanted to get this thing done! Except for the sore hand, there were no incidences at all. The doctor insisted I eat some fruit & cheese during the process, to be sure my blood sugar didn't drop. Boyd Graves told me that I should expect a fever. I didn't get one, and was disappointed, till a couple days later, I became quite over-heated, and still am. I'll be going in for blood tests in a week or so, and have a "base-line" of recent tests, to measure anything that may happen. I have been taking vitamin C, at approximately 3 grams/day, and this has been raising my CD4's, over the last few months, by about 10+, at each 2 month testing. Any increases beyond that would likely be the result of tetrasil. Viral load increased, as CD4's increased, but it's still not all that high. We'll see if anything happens there. Graves' improvements occurred over time, and that is my expectation: months, a year, 2 years. It was difficult getting the procedure arranged. I scared of my Naturopath, and the doctor that finally did it, was nervous about it. Delays! Well, it's done, and if I got enough of the tetrasil into my body, there may be improvements to come. I'll post. Sssteve

30,000 DOA and 300,000 disabled Gulf War vets and their US families mainly from contagious sabotaged vaccines:


IP Logged

All times are CT (US)

next newest topic | next oldest topic

Administrative Options: Close Topic | Archive/Move | Delete Topic
Post New Topic  Post A Reply
Hop to:

Contact Us | Chemtrail Central

Ultimate Bulletin Board 5.45c